US Patent 11186555 Methods and compositions for gamma-glutamyl cycle modulation
Patent 11186555 was granted and assigned to Cancer Research Technology Limited on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+199 characters)
Article
Patent abstract
The present disclosure provides pharmaceutical compositions comprising Gamma-glutamyl cycle inhibitors (GGCI) and certain pharmaceutically acceptable salts thereof, and methods of use.
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111865550
Date of Patent
November 30, 2021
0Patent Application Number
164437950
Date Filed
June 17, 2019
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111865550
Date of Patent
November 30, 2021
0Patent Application Number
164437950
Date Filed
June 17, 2019
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Dec, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11186555 Methods and compositions for gamma-glutamyl cycle modulation
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11186555
Date of patent
November 30, 2021
Patent application number
16443795
Date Filed
June 17, 2019
Patent primary examiner
Find more entities like US Patent 11186555 Methods and compositions for gamma-glutamyl cycle modulation
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.